Analysis of failures in patients with stage I ovarian cancer: An Italian multicenter study

A. Gadducci, E. Sartori, T. Maggino, P. Zola, F. Landoni, A. Fanucchi, C. Stegher, C. Alessi, F. Buttitta, T. Bergamino

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The objective of this retrospective multicenter study was to assess the rates, times, sites, and risk factors for recurrences in 224 patients with surgical stage I ovarian cancer. Postoperative adjuvant treatment was given to 153 of these patients. One hundred and eighty-two (81.3%) patients are currently alive with no clinical evidence of disease after a median time of 84 months (range, 4-191 months) from surgery, whereas 39 (17.4%) developed recurrent disease after a median time of 29 months (range, 5-112 months). The relapse involved the pelvis in 21 (53.8%) cases, abdomen in 19 (48.7%), pelvic and/or para-aortic lymph nodes in 5 (12.8%), and distant sites in 5 (12.8%). The risk of recurrence was significantly related to FIGO substage (P <0.0001) and tumor grade (P <0.0001), but not to histological subtype. However, the recurrence rate was lower in mucinous carcinomas (6/52, 11.5%) and higher in clear cell carcinomas (5/14, 35.7%). By log-rank test the disease-free survival was significantly related to FIGO substage (P = 0.0006) and grade (P = 0.0001). Cox proportional hazard model showed that grade was the only independent prognostic variable for disease-free survival, with a risk ratio for relapse of 2.831 (95% CI, 1.120-6.624) for grade 2 and 7.725 (95% CI, 3.290-18.140) for grade 3, compared to grade 1. In conclusion, tumor grade is the strongest predictor of recurrence in stage I ovarian cancer.

Original languageEnglish
Pages (from-to)445-450
Number of pages6
JournalInternational Journal of Gynecological Cancer
Volume7
Issue number6
Publication statusPublished - 1997

Fingerprint

Ovarian Neoplasms
Multicenter Studies
Recurrence
Disease-Free Survival
Mucinous Adenocarcinoma
Pelvis
Proportional Hazards Models
Abdomen
Neoplasms
Retrospective Studies
Lymph Nodes
Odds Ratio
Carcinoma

Keywords

  • Grade
  • Histologic type
  • Ovarian cancer
  • Prognosis
  • Recurrence
  • Stage

ASJC Scopus subject areas

  • Cancer Research
  • Obstetrics and Gynaecology
  • Oncology

Cite this

Gadducci, A., Sartori, E., Maggino, T., Zola, P., Landoni, F., Fanucchi, A., ... Bergamino, T. (1997). Analysis of failures in patients with stage I ovarian cancer: An Italian multicenter study. International Journal of Gynecological Cancer, 7(6), 445-450.

Analysis of failures in patients with stage I ovarian cancer : An Italian multicenter study. / Gadducci, A.; Sartori, E.; Maggino, T.; Zola, P.; Landoni, F.; Fanucchi, A.; Stegher, C.; Alessi, C.; Buttitta, F.; Bergamino, T.

In: International Journal of Gynecological Cancer, Vol. 7, No. 6, 1997, p. 445-450.

Research output: Contribution to journalArticle

Gadducci, A, Sartori, E, Maggino, T, Zola, P, Landoni, F, Fanucchi, A, Stegher, C, Alessi, C, Buttitta, F & Bergamino, T 1997, 'Analysis of failures in patients with stage I ovarian cancer: An Italian multicenter study', International Journal of Gynecological Cancer, vol. 7, no. 6, pp. 445-450.
Gadducci A, Sartori E, Maggino T, Zola P, Landoni F, Fanucchi A et al. Analysis of failures in patients with stage I ovarian cancer: An Italian multicenter study. International Journal of Gynecological Cancer. 1997;7(6):445-450.
Gadducci, A. ; Sartori, E. ; Maggino, T. ; Zola, P. ; Landoni, F. ; Fanucchi, A. ; Stegher, C. ; Alessi, C. ; Buttitta, F. ; Bergamino, T. / Analysis of failures in patients with stage I ovarian cancer : An Italian multicenter study. In: International Journal of Gynecological Cancer. 1997 ; Vol. 7, No. 6. pp. 445-450.
@article{eab4ea6cd66e43c9aaf36ee08f6badee,
title = "Analysis of failures in patients with stage I ovarian cancer: An Italian multicenter study",
abstract = "The objective of this retrospective multicenter study was to assess the rates, times, sites, and risk factors for recurrences in 224 patients with surgical stage I ovarian cancer. Postoperative adjuvant treatment was given to 153 of these patients. One hundred and eighty-two (81.3{\%}) patients are currently alive with no clinical evidence of disease after a median time of 84 months (range, 4-191 months) from surgery, whereas 39 (17.4{\%}) developed recurrent disease after a median time of 29 months (range, 5-112 months). The relapse involved the pelvis in 21 (53.8{\%}) cases, abdomen in 19 (48.7{\%}), pelvic and/or para-aortic lymph nodes in 5 (12.8{\%}), and distant sites in 5 (12.8{\%}). The risk of recurrence was significantly related to FIGO substage (P <0.0001) and tumor grade (P <0.0001), but not to histological subtype. However, the recurrence rate was lower in mucinous carcinomas (6/52, 11.5{\%}) and higher in clear cell carcinomas (5/14, 35.7{\%}). By log-rank test the disease-free survival was significantly related to FIGO substage (P = 0.0006) and grade (P = 0.0001). Cox proportional hazard model showed that grade was the only independent prognostic variable for disease-free survival, with a risk ratio for relapse of 2.831 (95{\%} CI, 1.120-6.624) for grade 2 and 7.725 (95{\%} CI, 3.290-18.140) for grade 3, compared to grade 1. In conclusion, tumor grade is the strongest predictor of recurrence in stage I ovarian cancer.",
keywords = "Grade, Histologic type, Ovarian cancer, Prognosis, Recurrence, Stage",
author = "A. Gadducci and E. Sartori and T. Maggino and P. Zola and F. Landoni and A. Fanucchi and C. Stegher and C. Alessi and F. Buttitta and T. Bergamino",
year = "1997",
language = "English",
volume = "7",
pages = "445--450",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Analysis of failures in patients with stage I ovarian cancer

T2 - An Italian multicenter study

AU - Gadducci, A.

AU - Sartori, E.

AU - Maggino, T.

AU - Zola, P.

AU - Landoni, F.

AU - Fanucchi, A.

AU - Stegher, C.

AU - Alessi, C.

AU - Buttitta, F.

AU - Bergamino, T.

PY - 1997

Y1 - 1997

N2 - The objective of this retrospective multicenter study was to assess the rates, times, sites, and risk factors for recurrences in 224 patients with surgical stage I ovarian cancer. Postoperative adjuvant treatment was given to 153 of these patients. One hundred and eighty-two (81.3%) patients are currently alive with no clinical evidence of disease after a median time of 84 months (range, 4-191 months) from surgery, whereas 39 (17.4%) developed recurrent disease after a median time of 29 months (range, 5-112 months). The relapse involved the pelvis in 21 (53.8%) cases, abdomen in 19 (48.7%), pelvic and/or para-aortic lymph nodes in 5 (12.8%), and distant sites in 5 (12.8%). The risk of recurrence was significantly related to FIGO substage (P <0.0001) and tumor grade (P <0.0001), but not to histological subtype. However, the recurrence rate was lower in mucinous carcinomas (6/52, 11.5%) and higher in clear cell carcinomas (5/14, 35.7%). By log-rank test the disease-free survival was significantly related to FIGO substage (P = 0.0006) and grade (P = 0.0001). Cox proportional hazard model showed that grade was the only independent prognostic variable for disease-free survival, with a risk ratio for relapse of 2.831 (95% CI, 1.120-6.624) for grade 2 and 7.725 (95% CI, 3.290-18.140) for grade 3, compared to grade 1. In conclusion, tumor grade is the strongest predictor of recurrence in stage I ovarian cancer.

AB - The objective of this retrospective multicenter study was to assess the rates, times, sites, and risk factors for recurrences in 224 patients with surgical stage I ovarian cancer. Postoperative adjuvant treatment was given to 153 of these patients. One hundred and eighty-two (81.3%) patients are currently alive with no clinical evidence of disease after a median time of 84 months (range, 4-191 months) from surgery, whereas 39 (17.4%) developed recurrent disease after a median time of 29 months (range, 5-112 months). The relapse involved the pelvis in 21 (53.8%) cases, abdomen in 19 (48.7%), pelvic and/or para-aortic lymph nodes in 5 (12.8%), and distant sites in 5 (12.8%). The risk of recurrence was significantly related to FIGO substage (P <0.0001) and tumor grade (P <0.0001), but not to histological subtype. However, the recurrence rate was lower in mucinous carcinomas (6/52, 11.5%) and higher in clear cell carcinomas (5/14, 35.7%). By log-rank test the disease-free survival was significantly related to FIGO substage (P = 0.0006) and grade (P = 0.0001). Cox proportional hazard model showed that grade was the only independent prognostic variable for disease-free survival, with a risk ratio for relapse of 2.831 (95% CI, 1.120-6.624) for grade 2 and 7.725 (95% CI, 3.290-18.140) for grade 3, compared to grade 1. In conclusion, tumor grade is the strongest predictor of recurrence in stage I ovarian cancer.

KW - Grade

KW - Histologic type

KW - Ovarian cancer

KW - Prognosis

KW - Recurrence

KW - Stage

UR - http://www.scopus.com/inward/record.url?scp=6844237649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6844237649&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:6844237649

VL - 7

SP - 445

EP - 450

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 6

ER -